相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1971
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
• Exploratory analysis of the phase 3 DUO-E trial reveals olaparib maintenance added to durvalumab plus chemotherapy significantly improves progression-free survival across multiple biomarker subgroups in pMMR endometrial cancer. • The greatest risk reductions were observed in patients with detectable ctDNA at baseline (HR, 0.36), positive PD-L1 expression (HR, 0.44), and serous disease histology (HR, 0.46), demonstrating broad efficacy. • The triple combination extended median PFS to 15.1 months compared to 9.6 months with chemotherapy alone, representing a 45% reduction in progression or death risk (HR, 0.55; P<.0001).
• Phase 2 GOG 3026 trial demonstrates ribociclib plus letrozole achieves 24% response rate in low-grade serous ovarian cancer, surpassing current treatment options' efficacy. • The combination therapy shows favorable tolerability profile, building on established safety protocols from breast cancer treatment experience. • Researchers anticipate inclusion in NCCN guidelines, though optimal treatment timing and sequencing remain under investigation for future clinical trials.
